The goal of this study was to determine the efficacy of iniparib (BSI-201/SAR240550) in patients with breast cancer gene-associated (BRCA) ovarian cancer.

Up to 35 patients were to be treated using a Simon 2-stage optimal design, i.e. twelve were to be treated in a first stage, then if 2/12 patients responded to treatment as defined by Response Evaluation Criteria in Solid Tumor (RECIST), 23 additional patients were be treated in the second stage.

Participants were treated for at least one 8-week cycle, with additional cycles as long as they had stable or responding disease (per RECIST criteria) and wished to remain on study.

Participants had a final follow-up visit within 4 weeks following the last dose of iniparib, after which time they were contacted by study staff every 3 months for the first year and every 6 months thereafter to assess disease status and survival.

Inclusion Criteria:

• Female, age 18 or older;
• Histologically or cytologically confirmed advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (stage III or IV);
• At least one previous regimen with platinum/taxane combination therapy and no curative options as determined by their physician (no limit on the number of prior therapies);
• Confirmed BRCA1 or BRCA2 status;
• One or more measurable lesions, at least 10mm in longest diameter by spiral computed tomography (CT) scan or 20mm in longest diameter when measured with conventional techniques (palpation, plain x-ray, CT or magnetic resonance imaging (MRI));
• Karnofsky performance status ≥70%;
• Estimated life expectancy of at least 16 weeks.

Exclusion Criteria:

• Normal clinical laboratory values;
• Any anti-cancer therapy within 21 days prior to study start;
• Any other malignancy within 3 years of study start, except adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of the breast, or basal or squamous cell skin cancer;
• Active viral infection including HIV/AIDS, Hepatitis B or Hepatitis C infection;
• Active central nervous system or brain metastases;
• History of seizures or current treatment with anti-epileptic medication;
• Persistent grade 2 or greater toxicities from prior therapy, excluding alopecia.